Microbot Medical Inc. reported its financial results for the second quarter of 2026, revealing a revenue of $241,000 for the three months ended June 30, 2026, and $346,000 for the six-month period, marking a significant shift from the previous year when the company had no revenue. The company attributed this revenue generation to the limited market release of its LIBERTY® Endovascular Robotic System, which transitioned to a full market release in April 2026. Despite the revenue, Microbot incurred a net loss of $5.6 million for the quarter and $9.3 million for the first half of the year, compared to losses of $3.5 million and $6.1 million in the same periods of 2025.
The company’s total assets decreased to $73.4 million as of June 30, 2026, down from $81.5 million at the end of 2025. This decline was primarily due to a reduction in cash and cash equivalents, which fell to $3.2 million from $3.9 million. The decrease in total assets was accompanied by a rise in total liabilities, which increased to $4.4 million from $4.0 million, largely due to higher accounts payable and lease liabilities. Shareholders' equity also saw a decline, dropping to $68.9 million from $77.6 million, reflecting the ongoing net losses.
Operationally, Microbot Medical has focused on expanding its market presence and product adoption. The company has ramped up its manufacturing efforts for the LIBERTY® system, which is designed for minimally invasive surgical procedures. As of June 30, 2026, the company had 67,164,801 shares of common stock outstanding. The company continues to monitor the geopolitical situation in Israel, where it is based, as ongoing regional conflicts could impact its operations and supply chain.
Looking ahead, Microbot Medical plans to continue its commercialization efforts for the LIBERTY® system and is exploring additional funding options to support its growth. The company has raised approximately $168.3 million since its inception, primarily through equity offerings and grants. Management believes that the available funds are sufficient to support operations for more than twelve months from the date of the financial statements. However, the company acknowledges the uncertainty surrounding future revenue generation and the need for additional capital to sustain its operations and growth initiatives.
About Microbot Medical Inc.
Microbot Medical Inc. develops minimally invasive robotic surgical devices, focusing on endovascular procedures. Its flagship LIBERTY system is a disposable, remotely operated robot designed to improve navigation, safety, and access in vascular interventions. The company targets global markets, including the U.S. and Europe, leveraging innovative technology, strategic partnerships, and regulatory approvals to establish its products as standards of care in interventional medicine.
About 10-Q Filings
A 10-Q form is an important financial report that public companies in the United States must submit every three months. It gives a clear picture of a company's financial health and recent performance.
Key points about the 10-Q:
- Frequency: Companies file it three times a year, covering the first three quarters. The fourth quarter is covered in a more comprehensive annual report.
-
Content: It includes:
- Financial statements showing the company's current financial position
- Updates from management on the performance and projections of the business
- Information about potential risks the company faces
- Details on how the company is run internally
- Deadline: Must be filed within 40 or 45 days after the quarter ends, depending on the size of the company.
Our Methodology
AssetRoom is committed to providing timely summaries of news from public companies. We use AI to generate these summaries quickly, but they are not reviewed by human experts.
Our method:
- Data Collection: We continuously monitor for new filings (currently limited to US-listed stocks).
- AI-Powered Analysis: Our advanced AI system processes each filing, identifying key information and extracting relevant data.
- Summary Generation: The AI creates a concise, easy-to-understand summary of the filing, highlighting the most important points.
- Publication: The summary is immediately published on our platform, allowing users instant access to the latest information.
- Email users: We distribute round-up emails according to our users preferences, keeping them in the loop with the companies they follow.
Feedback & Corrections
Spot an error or have a suggestion? Contact us.
View the complete official filing on the SEC website.
Read on SEC.gov